PineTree Therapeutics Inc, a groundbreaking biotechnology company based in Cambridge, Massachusetts, has successfully raised $17 million in a recent funding round aimed at furthering its innovative research and development efforts. Focused on addressing critical unmet medical needs such as drug resistance and tumor recurrence, PineTree Therapeutics has pioneered the AbReptor™ platform, which specializes in the targeted degradation of disease-causing proteins. This pre-clinical stage firm is at the forefront of a new wave of therapeutic solutions that harness the unique mechanisms of novel degrader drugs. Unlike traditional receptor tyrosine kinase (RTK) inhibitors, which are hindered by specificity and severe toxicity, the AbReptor™ platform promises an exciting shift in cancer therapy. Preliminary studies of PineTree’s lead molecule have showcased an impressive on-target degradation capability and mutation-agnostic properties, effectively combating tumors that are resistant to current RTK inhibitors without inducing toxicity in exposed animal models. Moreover, this funding will allow PineTree to advance its ambitious agenda of exploring new avenues in the development of immune checkpoint inhibitors (ICIs), with their PD-(L)1 degrader poised to challenge traditional therapies. With plans to expand their platform across various target proteins, PineTree Therapeutics is committed to transforming the landscape of oncology and beyond. This notable infusion of capital not only empowers the company to continue its research initiatives but also reinforces its vision of revolutionizing medical treatment for patients suffering from challenging and resistant diseases.
Pinetree Therapeutics Inc Raises $17 Million in Series A Funding for Groundbreaking Drug Degradation Platform
Recently funded · $17.0M Series aBiotechnology
Get the full PineTree Therapeutics Inc company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
